Thrombocythemia, essential - Open Access .click

Results 51 to 60 of about 20,052 (177)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. [PDF]

, 2014
Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the myelo-erythroid lineage are overproduced and patients are predisposed to leukemic transformation.
de Haan, Gerald +3 more
core +1 more source

Aortic thrombus in a patient with myeloproliferative thrombocytosis, successfully treated by pharmaceutical therapy: a case report [PDF]

, 2010
Introduction Thrombosis in myeloproliferative thrombocytosis occurs usually in the microvessels and medium-sized arteries and veins and only rarely in the aorta. Aortic thrombosis is usually treated with thrombectomy.
Hidesuke Yamamoto +4 more
core +2 more sources

Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms [PDF]

, 2010
A loss-of-function mutation of TET2, CBL and CEBPA has been implicated in the pathogenesis or leukaemic transformation of myeloproliferative neoplasm.
Chim, CS, Fung, TK, Wan, TS, Wong, KF
core +1 more source

Mutant calreticulin—Cancer driver and Achilles' heel for ET?

HemaSphere, Volume 10, Issue 4, April 2026.
Moritz Reichert, Bethan Psaila
wiley +1 more source

Essential thrombocythemia and pregnancy [PDF]